1. Home
  2. ALAR vs CGTX Comparison

ALAR vs CGTX Comparison

Compare ALAR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alarum Technologies Ltd.

ALAR

Alarum Technologies Ltd.

HOLD

Current Price

$7.40

Market Cap

43.7M

Sector

Technology

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.08

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALAR
CGTX
Founded
2013
2007
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.7M
110.8M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
ALAR
CGTX
Price
$7.40
$1.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$14.00
$3.33
AVG Volume (30 Days)
36.1K
943.2K
Earning Date
05-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$24.51
N/A
Revenue Next Year
$33.43
N/A
P/E Ratio
$44.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.50
$0.22
52 Week High
$18.00
$3.83

Technical Indicators

Market Signals
Indicator
ALAR
CGTX
Relative Strength Index (RSI) 56.16 43.48
Support Level $7.27 $1.01
Resistance Level $7.82 $1.19
Average True Range (ATR) 0.61 0.09
MACD 0.01 -0.02
Stochastic Oscillator 53.30 5.45

Price Performance

Historical Comparison
ALAR
CGTX

About ALAR Alarum Technologies Ltd.

Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment: web data collection. Geographically, it derives maximum revenue from China, followed by the United States, Europe, Hong Kong, Asia-Pacific, U.K. Virgin Islands, Israel, United Arab Emirates, Middle East & Africa and other.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: